



ORIGINAL ARTICLE

# Absence of the influence of the *APOE* gene on the incidence of type 2 diabetes mellitus in a cohort of workers: Effect of diet and shift work



Rocío Mateo-Gallego<sup>a,b</sup>, Sofía Pérez-Calahorra<sup>b</sup>, Ana M. Bea<sup>a</sup>, Irene Gracia-Rubio<sup>a</sup>, Carmen Rodrigo-Carbo<sup>a</sup>, Belen Moreno-Franco<sup>a,c</sup>, Fernando Civeira<sup>a,d</sup>, Martín Laclaustra<sup>a,d</sup>, Itziar Lamiquiz-Moneo<sup>a,e,\*</sup>

<sup>a</sup> Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), CIBERCV, Zaragoza, Spain

<sup>b</sup> Departamento de Fisiología y Enfermería, Facultad de Ciencias de la Salud y del Deporte, Universidad de Zaragoza, Huesca, Spain

<sup>c</sup> Departamento de Medicina, Microbiología, Pediatría, Radiología y Salud Pública, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain

<sup>d</sup> Departamento de Medicina, Psiquiatría y Dermatología, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain

<sup>e</sup> Departamento de Anatomía Humana e Histología, Escuela de Medicina, Universidad de Zaragoza, Spain

Received 7 December 2022; accepted 12 April 2023

## KEYWORDS

*APOE* gene;  
Type 2 diabetes;  
Glucose;  
Shift work

## Abstract

**Background:** *APOE* gene encoded a multifunctional protein in lipid metabolism, also associated with inflammatory markers. Type 2 diabetes (T2D) is a complex metabolic disease related to increased blood glucose, triglycerides and VLDL and associated with different dyslipidaemias. The aim of this study was to analyze whether the *APOE* genotype could determining the risk of developing T2D in a large cohort of workers.

**Material and methods:** Data from the Aragon Workers Health Study (AWHS) ( $n = 4895$ ) were used to investigate the relationship between glycemic levels and *APOE* genotype. All patients in the AWHS cohort had their blood drawn after an overnight fast and laboratory tests were performed on the same day as the blood drawn. Dietary and physical assessment was assessed by face-to-face interview. *APOE* genotype was determined by the Sanger sequencing method.

**Results:** The relationship between *APOE* genotype and glycemic profile showed that glucose, Hb1Ac, insulin and HOMA levels did not seem to be associated with the *APOE* genotype ( $p = 0.563$ ,  $p = 0.605$ ,  $p = 0.333$  and  $p = 0.276$ , respectively). In addition, the T2D prevalence did not show an association with the *APOE* genotype ( $p = 0.354$ ). Along the same lines, blood glucose levels and T2D prevalence did not show association with the *APOE* allele. Shift work had some effect on the glycaemic profile, showing that night shift workers have significantly lower levels of

\* Corresponding author.

E-mail address: [itziarlamiquiz@unizar.es](mailto:itziarlamiquiz@unizar.es) (I. Lamiquiz-Moneo).

glucose, insulin and HOMA ( $p < 0.001$ ). However, the *APOE* genotype did not show difference in the concentration of glycaemic parameters adjusting by sex, age and BMI, work shift and dietary parameters.

**Conclusion:** Glycemic profile and T2D prevalence did not show any significant association with the *APOE* genotype. Besides, individuals, who worked in non-rotating night shift showed significantly lower glycemic levels, while workers in the morning-afternoon-night shift showed significantly higher values.

© 2023 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.

## PALABRAS CLAVE

Gen *APOE*;  
Diabetes tipo 2;  
Glucosa;  
Trabajo por turnos

## Ausencia de la influencia del gen *APOE* en la incidencia de diabetes mellitus tipo 2 en una cohorte de trabajadores: efecto de la dieta y la turnicidad laboral

### Resumen

**Introducción:** El gen *APOE* codifica una proteína multifuncional en el metabolismo de los lípidos y asociada con marcadores inflamatorios. La diabetes tipo 2 (T2D) es una enfermedad metabólica compleja relacionada con aumento de glucosa en sangre, triglicéridos y VLDL y asociado a diferentes dislipidemias. El objetivo de este estudio fue analizar si el genotipo *APOE* podría determinar el riesgo de desarrollar T2D en una gran cohorte de trabajadores.

**Material y métodos:** Se utilizaron datos de la cohorte Aragon Workers Health Study (AWHS) ( $n = 4895$ ) para investigar la relación entre los niveles glucémicos y el genotipo *APOE*. Se extrajo una muestra de sangre tras ayuno a todos los trabajadores de la AWHS y se realizaron pruebas de laboratorio el mismo día de la extracción de sangre. La evaluación dietética y física se evaluó mediante una entrevista presencial. El genotipo *APOE* se determinó por el método de secuenciación Sanger.

**Resultados:** La glucosa, los niveles de Hb1Ac, insulina y HOMA no parecen estar asociados con el genotipo *APOE* ( $p = 0.563$ ,  $p = 0.605$ ,  $p = 0.333$  y  $p = 0.276$ , respectivamente). Además, la prevalencia de T2D no mostró una asociación con el genotipo *APOE* ( $p = 0.354$ ). Del mismo modo, los niveles de glucosa en sangre y la prevalencia de T2D no mostró asociación con ningún alelo de *APOE*. El trabajo por turnos tuvo algún efecto en el perfil glucídico, mostrando que los trabajadores del turno de noche tienen niveles significativamente más bajos de glucosa, insulina y HOMA ( $p < 0.001$ ). Sin embargo, el genotipo *APOE* no mostró diferencia en la concentración de parámetros glucídicos ajustando por sexo, edad e IMC, jornada laboral y parámetros dietéticos.

**Conclusión:** El perfil glucídico y la prevalencia de T2D no mostraron una asociación significativa con el genotipo *APOE*. Además, los individuos que trabajaban en turno de noche no rotativo mostraron significativamente niveles glucídicos más bajos, mientras que los trabajadores del turno mañana-tarde noche mostraron valores significativamente más altos.

© 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Diabetes is one of the most common complex diseases, affecting approximately 460 million adults worldwide. Furthermore, this prevalence is projected to double by 2045. Type 2 diabetes (T2D) accounts for more than 90% of diabetes,<sup>1</sup> with variable contributions of insulin resistance and beta cell dysfunction, and influenced by multiple risk factors, including genetics.<sup>2</sup> Hundreds of loci associated with T2D have been identified in large-scale genetic studies, including genome-wide association studies (GWAS), accounting for approximately 20% of the variance in individual predisposition to T2D.<sup>3–5</sup> However, the limited effect of each of these variants means that they

have little weight in daily clinical practice. On the other hand, elevated serum triglyceride (TG) levels are strongly correlated with insulin resistance, elevated glucose levels, and T2D, however the association between the two components is not fully defined.<sup>6</sup> Epidemiological data support a possible etiological role of elevated TG levels in insulin resistance and T2D. Elevated serum TG predict incident T2D independently of body mass index (BMI), and elevated TG can be observed up to 10 years before T2D diagnosis.<sup>7,8</sup> In fact, different dyslipidaemias such as hypertriglyceridemia and familial combined hyperlipidemia, characterized by high very-low density lipoprotein (VLDL) particles and TG, are associated with a high risk of T2D.<sup>9</sup>

Apolipoprotein E (ApoE) is a multifunctional protein with central function in lipid and neurobiological metabolism, that in plasma mediates the clearance of remnant lipoproteins and at the endothelial level it is secreted by macrophages participating in the flow of cholesterol toward the atherosclerotic plaque.<sup>10,11</sup> ApoE has high affinity for the low-density lipoprotein (LDL) receptor, facilitates plasmatic lipoprotein hepatic and extrahepatic uptake and modulates the generation of new HDL particles.<sup>10</sup> ApoE is codified by the *APOE* gene, located in the chromosome 19, q13.32, which contains three common alleles (E2, E3, E4), producing three homozygous and three heterozygous genotypes. These polymorphisms determine different isoforms that differ in ApoE primary structure at residues 112 and 158.<sup>12</sup> In the human population ApoE3 is the most common (78%) followed by ApoE4 (14%) and ApoE2 (7%).<sup>13</sup> The receptor-binding function and lipid affinity of ApoE is remarkably specific to each isoform. Individuals carrying the ApoE4 allele have higher low-density lipoprotein cholesterol (LDLc) than those carrying the ApoE2 allele.<sup>14</sup> They are also associated with different disorders; while ApoE3 is considered the wild type isoform, ApoE2 may participate in the development of dysbetalipoproteinemia and ApoE4 in Alzheimer disease.<sup>11,13</sup>

Variants at the *APOE* locus are one of the strongest signals for LDLc, as confirmed by recent GWAS,<sup>15</sup> showing that E4 carriers reported not only have significantly higher levels of LDLc but also increased cardiovascular risk.<sup>16</sup> Also, *APOE* genotype has a relation with lipoprotein(a) (Lp(a)) and different inflammatory biomarkers, such as C-reactive protein.<sup>17</sup> On the other hand, the size of VLDL particle,<sup>18</sup> which are associated with a higher risk of developing T2D, could also be related with *APOE* locus.<sup>19</sup> Different studies have reported conflicting results between *APOE* genotype and T2D development.<sup>20,21</sup>

Lifestyle factors related to T2D incidence include physical activity level, dietary habits and, adiposity, among others.<sup>22</sup> In the last years, several studies have pointed out how circadian rhythms disruption could influence glycemic profile by increasing T2D risk.<sup>23,24</sup> To increase the knowledge of the influence of *APOE* genotype on glucose metabolism and if lifestyle patterns, as work shift, could affect that association would contribute to improve glycemic control and T2D prevention. Therefore, the objective of this study was to analyze how the *APOE* genotype could affect glycemic profile and the risk of T2D development in a large cohort of shift workers.

## Material and methods

### Subjects

The Aragon Workers Health Study (AWHS) is a longitudinal cohort study, started in 2009 based on the Spain automobile assembly plant (Zaragoza, Spain) and involves workers' annual medical examinations and biological samples.<sup>25</sup> All workers were offered to participate in the study, and the response rate was 94.5%. The sample is predominantly male (>95%). Exclusion criteria include a history of cardiovascular disease or the presence of clinical conditions that limit survival to less than 3 years. The study was approved by

the central Institutional Review Board of Aragón (Comité Ético de Investigación Clínica de Aragón, CEICA). All study participants provided written informed consent.

T2D subjects were defined following the standards of medical care in diabetes from American Diabetes Association (ADA),<sup>26</sup> as those individuals who meet any of the following criteria: fasting blood glucose levels greater than 125 mg/dL, a glycosylated hemoglobin (HbA1c) greater than 6.4% or have been prescribed with any antidiabetic medication.

### Biochemical analytical

All patients from AWHS cohort were drawn blood after overnight fasting. Laboratory tests were performed on the same day of blood sampling. Fasting serum glucose, TG, total cholesterol and high-density lipoprotein cholesterol (HDLc) were measured by spectrophotometry (AU5800 Beckman Coulter Inc.) serum Apo A1 and B by kinetic nephelometry (Immunochemistry Analyzer IMMAGE 800, Beckman Coulter). Lp(a) concentration was measured by rate nephelometry using LPAX reagent in conjunction with IMMAGE Immunochemistry Systems and Lp(a) Calibrator (OMS/IFCC SRM 2 B) (Beckman Coulter), following manufacturer instructions. LDLc was calculated using Friedewald equation. Whole blood HbA1c was measured by reverse-phase cationic exchange chromatography and quantification by double wave-length colorimetric quantification (Analyzer ADAMS A1c HA-810, Arkray Factory). The HOMA-IR index is estimated with the product of fasting glucose (mg/dL) and fasting insulin ( $\mu$ U/mL) divided by 405.<sup>27</sup>

### Dietary and physical activity assessment

As previously published,<sup>28,29</sup> diet was assessed by a face-to-face interview through a 137 items semi-quantitative food frequency questionnaire that was previously validated in Spanish population.<sup>30</sup> Participants were asked about the average frequency of consumption and the serving size over the previous year. Food and nutrient intakes were calculated as frequency  $\times$  nutrient composition of specified portion sizes, where frequencies were measured in 9 categories (never, 1–3 times a month, 1 time a week, 2–4 times a week, 5–6 times a week, 1 time a day, 2–3 times a day, 4–6 times a day and >6 times a day) for each food item. The total energy and nutrients intakes were derived from Spanish food composition Tables.<sup>31</sup>

### Genetic analysis

Genomic DNA from whole blood samples was isolated using standard methods. Exon 4 of *APOE* gene was amplified by polymerase chain reaction and purified by ExoSap-IT (USB), as previously described.<sup>32</sup> Amplified fragments were sequenced by the Sanger method using the BigDye 3.1 sequencing kit (Applied Biosystems) in an automated ABI 3500xL sequencer (Applied Biosystems). DNA sequences were analyzed using Variant Reporter software (Applied Biosystems).

## Statistical analysis

Continuous variables are expressed as mean  $\pm$  SD or median [25th percentile – 75th percentile] as applicable and categorical (nominal) variables are reported as percentages of the total sample. The  $p$  value was calculated by ANOVA test or Kruskal–Wallis and Chi-square, as appropriate. The relationship between glucose profile and *APOE* genotype was studied by age, sex and body mass adjusted regression models. All statistical analyses were performed with R version 3.5.0 and significance was set at  $p < 0.05$ .<sup>33</sup>

## Results

**Table 1** shows clinical and biochemical characteristics according to *APOE* genotype of 4895 subjects from AWHs cohort. As we expected, total, LDL and HDL cholesterol and TG levels were significantly different according to *APOE* genotype ( $p < 0.001$ ,  $p < 0.001$ ,  $p = 0.047$  and  $p < 0.001$  respectively, **Table 1**). Total and LDLc and apo B were significantly higher in ApoE4 carriers than ApoE3 carriers and ApoE2, and the lowest total and LDL cholesterol and apo B were in ApoE2/E2 subjects. However, ApoE2E2 subjects had higher values of TG. Hypertension, smoking habit, liver enzymes and thyroid stimulating hormone were not associated with the *APOE* genotype (**Table 1**).

The relationship between *APOE* genotype and glycemic profile, showed that neither glucose, Hb1Ac, insulin levels and HOMA seem to be associated with the *APOE* genotype ( $p = 0.563$ ,  $p = 0.605$ ,  $p = 0.333$  and  $p = 0.276$ , respectively, **Fig. 1**). However, analyzing the relationship between the *APOE* genotype and glycemic profile in each sex, we found that only Hb1Ac levels are significantly associated with ApoE4E4 genotype in men ( $p = 0.031$ ). Following the ADA criteria, 332 subjects were diagnosed as T2D, that represents a prevalence of 7.90% in our cohort. Of the 332 subjects with a diagnosis of T2D, 168 (50.8%) received a hypoglycemic medication. The prevalence of T2D did not show any association with the *APOE* genotype ( $p = 0.354$ ).

When we categorized the *APOE* genotype in three groups, ApoE2 carriers, that included subjects with ApoE2/E2 and ApoE2/E3 genotypes, ApoE3 carriers, which included only subjects with ApoE3/E3 genotype, and ApoE4 carriers, which included subjects with ApoE3/E4, and ApoE4/E4 genotype, similar associations were found (**Table 2**). As expected, ApoE4 carriers had significantly higher values of LDL cholesterol and apo B and lower values of apo A1 than ApoE3 carriers and ApoE2 carriers ( $p < 0.001$  for all cases, **Table 2**).

Analyzing the relationship between *APOE* alleles and glycemic profile, we found that neither glucose, Hb1Ac, insulin levels and HOMA seem to have any association with the *APOE* alleles ( $p = 0.745$ ,  $p = 0.808$ ,  $p = 0.389$  and  $p = 0.497$ , respectively, **Fig. 2**) nor the prevalence of T2D ( $p = 0.978$ ).

Of the 4895 subjects from AWHs, 2378 subjects (48.6%) had available data of work shift and dietary habits assessment. **Table 3** shows the effect of shift work on the glycaemic profile, showing that glucose, insulin and HOMA levels are significantly different depending on the shift work. Night shift workers have significantly lower levels of glucose, insulin and HOMA ( $p < 0.001$  in all cases, **Table 3**). **Fig. 3**

shows correlations between glycaemic parameters and food items consumption, reporting that glucose and HOMA levels had negative significant association with fiber, carbohydrates and protein consumption and positive significant association with fat intake ( $p < 0.01$ , with fiber and  $p < 0.05$  with carbohydrate, protein and fat intake). However, when we analyzed if the *APOE* genotype could influence in the glycaemic profile adjusted by work shift and dietary parameters, we found that there were not differences in the concentration of glucose, insulin, Hb1Ac and HOMA depending on the *APOE* genotype ( $p = 0.372$ ,  $p = 0.681$ ,  $p = 0.813$  and  $p = 0.574$ , adjusted for age, weight, work shift and total consumption of carbohydrates, proteins and lipids, respectively, **Supplemental Table 1**). In the same line, there were not differences in the concentration of glucose, insulin, Hb1Ac and HOMA depending on the *APOE* allele ( $p = 0.356$ ,  $p = 0.255$ ,  $p = 0.956$  and  $p = 0.167$ , respectively, adjusted for age, weight, work shift and total consumption of carbohydrates, proteins and lipids, **Supplemental Table 2**).

## Discussion


This study shows that the development of T2D appears to be unrelated to the *APOE* gene after analysing the association between the *APOE* genotype and glucose, insulin, Hb1Ac, and HOMA values in a large cohort of workers from Zaragoza, Spain. However, those results suggest the existence of a relationship between glucose metabolism and work shifts.

Some previous studies have analyzed the relationship between *APOE* genotypes and the development of T2D, showing contradictory results. In the case of the meta-analysis, carried out by Chen et al.,<sup>21</sup> authors concluded that ApoE4 allele and ApoE2/E2, ApoE3/E4, and ApoE4/E4 genotypes are associated with the increased risk of the development of T2D. However, the meta-analysis carried out by Anthopoulos et al.,<sup>34</sup> concluded that only *APOE2* carriers seem to have a higher risk of developing T2D, indicating that this higher risk of the ApoE2 allele could be mediated by the alteration of lipid levels. However, in the case of our study, although we found that the serum concentration of TG is lower in individuals with the ApoE3/E4 and ApoE4/E4 genotypes, we did not find that ApoE2 carriers present significantly higher values of glucose, Hb1Ac, insulin or HOMA levels. In one recently study carried out by Gao et al.,<sup>20</sup> authors showed that T2D patients have significantly higher frequencies of ApoE3/E4 genotype and allele ApoE4. Besides, these authors reported that *APOE* allele is not only a risk factor to T2D development, but also its complications, indicating that E4 allele may be a risk factor for CVD in T2D, and cerebral infraction in T2D subjects, while the *APOE2* allele may be a risk factor for diabetic nephropathy. Another article with Chinese population showed that E4 allele was associated with a significantly increased risk of metabolomic syndrome, which often includes diabetes, only in men. Similar results we have found in our cohort, where only the Hb1Ac levels are significantly associated with E4 allele in men. Finally, one study carried out with 284 subjects categorized in three groups: T2D subjects, T2D subjects with complications and subjects with CVD, showed that only the frequency of ApoE3/E4 genotype and ApoE4 allele were significantly increased in CVD patients and not in T2D subjects.

**Table 1** Clinical and biochemical characteristics according to APOE genotype.

|                                  | $\epsilon 2/\epsilon 2$ (N = 20) | $\epsilon 2/\epsilon 3$ (N = 507) | $\epsilon 2/\epsilon 4$ (N = 59) | $\epsilon 3/\epsilon 3$ (N = 3456) | $\epsilon 3/\epsilon 4$ (N = 810) | $\epsilon 4/\epsilon 4$ (N = 43) | <i>p</i> |
|----------------------------------|----------------------------------|-----------------------------------|----------------------------------|------------------------------------|-----------------------------------|----------------------------------|----------|
| <i>Age, years</i>                | 51.0 (44.8–53.0)                 | 51.0 (44.0–54.0)                  | 52.0 (48.0–54.5)                 | 50.0 (45.0–54.0)                   | 50.0 (45.0–54.0)                  | 51.0 (48.0–54.0)                 | 0.515    |
| <i>Men, n (%)</i>                | 20 (100%)                        | 474 (93.5%)                       | 55 (93.2%)                       | 3247 (94.0%)                       | 760 (93.8%)                       | 41 (95.3%)                       | 0.892    |
| <i>Body weight, kg</i>           | 84.0 (74.2–87.3)                 | 79.6 (72.8–88.0)                  | 79.9 (72.5–90.1)                 | 80.0 (72.3–88.0)                   | 79.9 (71.5–87.9)                  | 79.0 (70.5–86.9)                 | 0.821    |
| <i>Total cholesterol, mg/dL</i>  | 182 (152–212)                    | 201 (177–226)                     | 225 (184–245)                    | 211 (186–236)                      | 215 (190–242)                     | 228 (194–254)                    | <0.001   |
| <i>LDL cholesterol, mg/dL</i>    | 88.5 (80.2–113)                  | 115 (94.8–137)                    | 135 (98.2–151)                   | 130 (109–152)                      | 136 (112–155)                     | 136 (118–164)                    | <0.001   |
| <i>Triglycerides, mg/dL</i>      | 170 (105–268)                    | 130 (89.0–193)                    | 140 (97.0–225)                   | 115 (81.0–170)                     | 117 (84.3–173)                    | 144 (106–204)                    | <0.001   |
| <i>HDL cholesterol, mg/dL</i>    | 47.0 (41.8–56.5)                 | 52.0 (45.0–59.0)                  | 54.0 (45.5–62.0)                 | 52.0 (46.0–60.0)                   | 51.0 (44.0–58.0)                  | 53.0 (43.5–59.0)                 | 0.047    |
| <i>Apolipoprotein A1, mg/dL</i>  | 141 (135–161)                    | 142 (133–157)                     | 142 (133–154)                    | 141 (130–154)                      | 139 (127–151)                     | 142 (134–158)                    | <0.001   |
| <i>Apolipoprotein B, mg/dL</i>   | 58.5 (49.2–70.3)                 | 94.0 (78.0–109)                   | 107 (83.0–119)                   | 104 (88.0–121)                     | 109 (93.5–124)                    | 123 (95.8–134)                   | <0.001   |
| <i>Hypertension, n (%)</i>       | 5 (25.0%)                        | 74 (14.6%)                        | 14 (23.7%)                       | 605 (17.5%)                        | 143 (17.7%)                       | 11 (39.5%)                       | 0.237    |
| <i>Smoking habit, n (%)</i>      |                                  |                                   |                                  |                                    |                                   |                                  |          |
| No smoker                        | 9 (45.0%)                        | 123 (24.4%)                       | 13 (26.5%)                       | 914 (26.7%)                        | 236 (29.4%)                       | 9 (20.9%)                        | 0.076    |
| Smoker                           | 6 (30.0%)                        | 210 (41.7%)                       | 17 (34.7%)                       | 1269 (37.0%)                       | 287 (35.8%)                       | 20 (46.5%)                       |          |
| Former smoker                    | 5 (25.0%)                        | 170 (33.8%)                       | 19 (38.7%)                       | 1240 (37.0%)                       | 279 (34.8%)                       | 14 (32.6%)                       |          |
| <i>GGT, UI/L</i>                 | 32.5 (24.0–42.8)                 | 34.0 (26.0–48.0)                  | 37.0 (25.5–51.0)                 | 34.0 (26.0–47.0)                   | 34.0 (26.0–48.0)                  | 34.0 (23.0–46.0)                 | 0.865    |
| <i>GOT, UI/L</i>                 | 23.0 (19.5–28.0)                 | 23.0 (20.0–27.0)                  | 24.0 (20.0–28.5)                 | 23.0 (20.0–27.0)                   | 23.0 (20.0–27.0)                  | 24.0 (20.5–28.0)                 | 0.605    |
| <i>GPT, UI/L</i>                 | 25.0 (18.8–30.8)                 | 24.0 (19.0–32.0)                  | 26.0 (20.5–38.0)                 | 24.0 (19.0–32.0)                   | 24.0 (19.0–32.0)                  | 27.0 (19.5–33.5)                 | 0.548    |
| <i>TSH, <math>\mu</math>U/mL</i> | 1.40 (1.08–1.70)                 | 1.37 (1.03–1.94)                  | 1.40 (1.00–2.13)                 | 1.45 (1.02–2.00)                   | 1.48 (1.06–1.96)                  | 1.54 (1.16–1.91)                 | 0.964    |

Quantitative variables are expressed as means  $\pm$  standard deviation, except for variables not following normal distribution that are expressed as medians (interquartile ranges). Qualitative variables are expressed as percentage. The *p* value was calculated by ANOVA test or Kruskal–Wallis and Chi-square, as appropriate. LDL: low density lipoprotein; HDL: high density lipoprotein; GGT: gamma-glutamyl transferase; GOT: aspartate aminotransferase; GPT: alanine aminotransferase; TSH: thyroid stimulating hormone.



**Figure 1** Glucose, Hb1Ac, Insulin and HOMA levels according to APOE genotype. The *p* value was calculated by lineal regression model adjusting by age, sex and BMI.

**Table 2** Clinical and biochemical characteristics according to APOE allele.


|                          | Allele $\epsilon 2$ (N = 527) | Allele $\epsilon 3$ (N = 3456) | Allele $\epsilon 4$ (N = 853) | Overall <i>p</i> | <i>p</i> <sup>1</sup> | <i>p</i> <sup>2</sup> | <i>p</i> <sup>3</sup> |
|--------------------------|-------------------------------|--------------------------------|-------------------------------|------------------|-----------------------|-----------------------|-----------------------|
| Age, years               | 51.0 (44.0–54.0)              | 50.0 (45.0–54.0)               | 50.0 (45.0–54.0)              | 0.795            | 0.574                 | 0.908                 | 0.640                 |
| Men, n (%)               | 494 (93.7%)                   | 3247 (94.0%)                   | 801 (93.9%)                   | 0.982            | 0.925                 | 0.993                 | 0.990                 |
| Body weight, kg          | 79.7 (72.8–88.0)              | 80.0 (72.3–88.0)               | 79.9 (71.4–87.8)              | 0.683            | 0.848                 | 0.669                 | 0.382                 |
| Total cholesterol, mg/dL | 201 (175–226)                 | 211 (186–236)                  | 216 (191–243)                 | <0.001           | <0.001                | <0.001                | <0.001                |
| LDL cholesterol, mg/dL   | 114 (92.8–136)                | 130 (109–152)                  | 136 (112–156)                 | <0.001           | <0.001                | <0.001                | <0.001                |
| Triglycerides, mg/dL     | 132 (90.5–195)                | 115 (81.0–170)                 | 118 (85.0–175)                | <0.001           | <0.001                | 0.016                 | 0.031                 |
| HDL cholesterol, mg/dL   | 52.0 (45.0–59.0)              | 52.0 (46.0–60.0)               | 51.0 (44.0–58.0)              | 0.016            | 0.834                 | 0.075                 | 0.004                 |
| Lipoprotein a, mg/dL     | 17.0 (7.55–41.9)              | 18.8 (9.00–43.0)               | 20.0 (8.00–46.0)              | 0.108            | 0.121                 | 0.039                 | 0.239                 |
| Apolipoprotein A1, mg/dL | 142 (133–157)                 | 141 (130–154)                  | 139 (127–152)                 | <0.001           | 0.007                 | <0.001                | 0.001                 |
| Apolipoprotein B, mg/dL  | 92.9 (77.0–109)               | 104 (88.0–121)                 | 109 (93.9–125)                | <0.001           | <0.001                | <0.001                | <0.001                |
| Hypertension, n (%)      | 79 (15.0%)                    | 605 (17.5%)                    | 154 (18.1%)                   | 0.345            | 0.194                 | 0.192                 | 0.792                 |
| Smoker habit, n (%)      |                               |                                |                               |                  |                       |                       |                       |
| No smoker                | 132 (25.0%)                   | 914 (26.4%)                    | 245 (28.8%)                   | 0.224            | 0.175                 | 0.144                 | 0.393                 |
| Smoker                   | 216 (40.9%)                   | 1269 (36.7%)                   | 307 (36.0%)                   |                  |                       |                       |                       |
| Former smoker            | 175 (33.2%)                   | 1240 (35.9%)                   | 293 (34.3%)                   |                  |                       |                       |                       |
| GGT, UI/L                | 34.0 (26.0–48.0)              | 34.0 (26.0–47.0)               | 34.0 (26.0–48.0)              | 0.966            | 0.888                 | 0.962                 | 0.809                 |
| GOT, UI/L                | 23.0 (20.0–27.0)              | 23.0 (20.0–27.0)               | 23.0 (20.0–27.0)              | 0.516            | 0.656                 | 0.288                 | 0.333                 |
| GPT, UI/L                | 24.0 (19.0–32.0)              | 24.0 (19.0–32.0)               | 24.0 (19.0–32.0)              | 0.836            | 0.598                 | 0.842                 | 0.717                 |
| TSH, $\mu$ U/mL          | 1.37 (1.03–1.93)              | 1.45 (1.02–2.00)               | 1.48 (1.06–1.96)              | 0.705            | 0.462                 | 0.389                 | 0.824                 |

Quantitative variable was expressed as mean  $\pm$  standard deviation, except for variables not following normal distribution that are expressed as medians (interquartile ranges). The overall *p* value was calculated by ANOVA test or Kruskal–Wallis and Chi-square, as appropriate. *p*<sup>1</sup>, *p*<sup>2</sup>, and *p*<sup>3</sup> values were calculated by *T*-Student test, *U* Mann–Whitney and Chi-square as appropriate, comparing  $\epsilon 2$  vs  $\epsilon 3$  carriers,  $\epsilon 2$  vs  $\epsilon 4$  carriers and  $\epsilon 3$  vs  $\epsilon 4$  carriers, respectively. <sup>2</sup>E2 allele included subjects with E2/2 and E2/3 APOE genotype. <sup>3</sup>E3 allele included only subjects with E3/3 APOE genotype. <sup>4</sup>E4 allele included subjects with E3/4 and E4/4 APOE genotype. LDL: low density lipoprotein; HDL: high density lipoprotein; GGT: gamma-glutamyl transferase; GOT: aspartate aminotransferase; GPT: alanine aminotransferase; TSH: thyroid stimulating hormone.

Besides, these authors concluded that after adjustment for other established risk factors, ApoE3/E4 genotype was an independent risk factor for CVD but not for T2D.<sup>35</sup>

Regarding work shifts, this study directly relates glucose, Hb1Ac and insulin levels with work shifts, by showing higher levels in individuals with morning-afternoon and

morning-afternoon-night rotating shifts. Evidence has been found that shift work significantly raises blood glucose concentration and decreases insulin sensitivity.<sup>36,37</sup> In addition, another study carried out in the United Kingdom points in the same way, and also adds that rotating night shifts increase the possibility of suffering from T2D, which



**Figure 2** Glucose, Hb1Ac, Insulin and HOMA levels according to *APOE* allele. The *p* value was calculated by lineal regression model adjusting by age, sex and BMI.

**Table 3** Effect of shift work on the glycaemic profile.

|                     | Rotating<br>morning–afternoon<br>shift (N = 1430) | Rotating shift<br>morning–afternoon<br>night (N = 468) | Center shift<br>(N = 247) | Night shift<br>(N = 233) | <i>p</i> |
|---------------------|---------------------------------------------------|--------------------------------------------------------|---------------------------|--------------------------|----------|
| Glucose, mg/dL      | 97.0 (91.0–105)                                   | 95.0 (88.8–103)                                        | 99.0 (93.0–106)           | 85.0 (78.0–93.0)         | <0.001   |
| Hb1Ac, %            | 5.40 (5.20–5.60)                                  | 5.40 (5.25–5.60)                                       | 5.40 (5.20–5.58)          | 5.40 (5.30–5.60)         | 0.158    |
| Insulin, $\mu$ U/mL | 5.70 (3.90–8.20)                                  | 6.50 (4.50–9.10)                                       | 5.25 (3.80–7.60)          | 4.90 (3.30–7.60)         | <0.001   |
| HOMA                | 1.36 (0.90–2.01)                                  | 1.50 (1.02–2.30)                                       | 1.28 (0.90–1.97)          | 1.04 (0.70–1.64)         | <0.001   |


Quantitative variable was expressed as median (interquartile ranges). The *p* value was calculated by Kruskal–Wallis test.

is consistent with the findings of this study, since workers with rotating schedules that include night shifts have the worst insulin levels.<sup>38</sup> Rotating shifts have previously been associated with circadian rhythm disorders<sup>39,40</sup> and more with pancreatic beta cell dysfunction and peripheral insulin resistance,<sup>41</sup> facts that are confirmed by our results. This would explain why changing shifts is worse than always going at night, due to the alteration of circadian rhythms, among other factors. According to another study conducted in the AWHs cohort by Peñalvo et al.,<sup>42</sup> the foregoing can be explained by the demanding schedules of rotating shift workers, which would be an important cause of the less healthy eating behaviors of these individuals, consisting of a higher intake of trans-saturated fats, coffee and soft drinks, in addition to less physical activity. The combination of all these factors could also be found behind the greater appearance of T2D and the parameters associated with it, despite the fact that in this study it is associated with atherosclerosis.

Regarding diet, a negative correlation was observed between the consumption of carbohydrates, fiber and protein and glucose concentration. However, we found a positive correlation between fat and blood glucose levels. The negative correlation between the consumption of carbohydrates and fiber with blood glucose, as well as the

positive correlation with the consumption of fats, could be explained by the insulin resistance that appears in cases of obesity. Insulin resistance would be caused by the consumption of foods rich in fat and very low in fiber, as is often the case with ultra-processed foods. There are studies that support that evaluating the total content of fats and carbohydrates in the diet may not yield significant information, so it is necessary to categorize the type of fat consumed. Since the consumption of monounsaturated fats and carbohydrates with a lower glycemic index and more fiber are associated with improvements in insulin resistance.<sup>43–45</sup>

Our study has some limitations that deserve comment. First of all, it is necessary to take into account the storage conditions that can especially affect the determination of glucose in samples from the night shift. This is due to the fact that if the centrifugation of the samples is not immediate, the erythrocytes present in the sample continue to consume glucose, which may partly explain the somewhat lower glucose values of the individuals on the night shift. However, glycosylated hemoglobin and insulin have the same trend, showing lower values in the night shift group, which seems to indicate that the storage conditions were ideal and did not affect glucose levels excessively. Secondly, the vast majority of the AWHs cohort is male. This prevalence of male patients could have important drawbacks on the reported



**Figure 3** Correlation between glycaemic parameters and food consumption markers. The  $p$  value was calculated by Spearman method. \*Denotes  $p$  value < 0.05; \*\*denotes  $p$ -value < 0.01 and \*\*\* denotes  $p$ -value < 0.001.

conclusions of the same. Since, as the ANIBES study has shown, men have a higher average consumption of processed food, sauces and condiments than women, who usually consume more fruit and vegetables.<sup>46</sup> However, despite the fact that obesity, which is the main conditioning factor of T2D, is more frequent among women, the prevalence of T2D is relatively higher in men, due to the greater accumulation of visceral fat that these individuals present.<sup>47</sup> Finally, having all the data on dietary habits for the entire AWHs cohort would allow us to include this variable and job shift in the regression models and further adjust the analysis prepared.

In summary, our study has reported that T2D prevalence in a large cohort of workers from a factory did not show any significant correlation with *APOE* genotype or allele. Glucose, insulin and HbA1c levels also did not show a significant correlation with *APOE* genotype. Besides, individuals working in non-rotating night shift showed significantly lower levels of glucose, insulin and HbA1c, while rotating morning-afternoon-night shift workers showed significantly higher levels of glucose, insulin and HbA1c.

## Funding

This work was supported by grants from Spanish Atherosclerosis Society ("Manuel de Oya" grant), from Aragon

Government, B14-7R, Spain, and the Spanish Ministry of Economy and competitiveness PI18/01777, PI19/0694, and CIBERCV. These projects are co-financed by Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) of the European Union "A way to make Europe". CIBERCV is a project of Instituto de Salud Carlos III.

## Conflict of interest

The authors declare no conflict of interest

## Acknowledgments

All authors have read and approved the final manuscript. The authors thank Cecilia Bennett for her English editorial assistance.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.arteri.2023.04.003>

## References

- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019;157:107843, <http://dx.doi.org/10.1016/j.diabres.2019.107843>.
- Redondo MJ, Hagopian WA, Oram R, Steck AK, Vehik K, Weedon M, et al. The clinical consequences of heterogeneity within and between different diabetes types. *Diabetologia.* 2020;63:2040–8, <http://dx.doi.org/10.1007/s00125-020-05211-7>.
- Udler MS, McCarthy MI, Florez JC, Mahajan A. Genetic risk scores for diabetes diagnosis and precision medicine. *Endocr Rev.* 2019;40:1500–20, <http://dx.doi.org/10.1210/er.2019-00088>.
- Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet.* 2018;50:1505–13, <http://dx.doi.org/10.1038/s41588-018-0241-6>.
- Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet.* 2020;52:680–91, <http://dx.doi.org/10.1038/s41588-020-0637-y>.
- Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. *Biochim Biophys Acta.* 2010;1801:299–310, <http://dx.doi.org/10.1016/j.bbalip.2009.10.007>.
- Wilson PWF, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. *Arch Intern Med.* 2007;167:1068–74, <http://dx.doi.org/10.1001/archinte.167.10.1068>.
- Hjellvik V, Sakshaug S, Strøm H. Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. *Clin Epidemiol.* 2012;4:213–24, <http://dx.doi.org/10.2147/CLEP.S31830>.
- Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA, de Graaf J, Stalenhoef AFH. The genetics of familial combined hyperlipidaemia. *Nat Rev Endocrinol.* 2012;8:352–62, <http://dx.doi.org/10.1038/nrendo.2012.15>.
- Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E – a multifunctional protein with implications in various pathologies as a result of its structural features. *Comput Struct Biotechnol J.* 2017;15:359–65, <http://dx.doi.org/10.1016/j.csbj.2017.05.003>.
- Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. *Neurobiol Dis.* 2014;72 Pt A:3–12, <http://dx.doi.org/10.1016/j.nbd.2014.08.025>.
- Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. *J Mol Med.* 2005;83:329–42, <http://dx.doi.org/10.1007/s00109-004-0631-3>.
- Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci.* 2009;10:333–44, <http://dx.doi.org/10.1038/nrn2620>.
- Bennet AM, Angelantonio ED, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein e genotypes with lipid levels and coronary risk. *JAMA.* 2007;298:1300–11, <http://dx.doi.org/10.1001/jama.298.11.1300>.
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical, and population relevance of 95 loci for blood lipids. *Nature.* 2010;466:707–13, <http://dx.doi.org/10.1038/nature09270>.
- Grammer TB, Hoffmann MM, Renner W, Kleber ME, Winkelmann BR, Böhm BO, et al. Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. *Atherosclerosis.* 2011;215:487–93, <http://dx.doi.org/10.1016/j.atherosclerosis.2011.01.005>.
- Civeira-Marín M, Cenarro A, Marco-Benedí V, Bea AM, Mateo-Gallego R, Moreno-Franco B, et al. APOE genotypes modulate inflammation independently of their effect on lipid metabolism. *Int J Mol Sci.* 2022;23:12947, <http://dx.doi.org/10.3390/ijms232112947>.
- Ramos-Cáceres M, Lamiquiz-Moneo I, Cenarro A, Calmarza P, Marco-Benedí V, Bea AM, et al. Triglyceride metabolism modifies lipoprotein(a) plasma concentration. *J Clin Endocrinol Metab.* 2022;dgac412, <http://dx.doi.org/10.1210/clinem/dgac412>.
- den Hartigh LJ, Altman R, Hutchinson R, Petrlova J, Budamagunta MS, Tetali SD, et al. Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation. *PLoS ONE.* 2012;7:e50513, <http://dx.doi.org/10.1371/journal.pone.0050513>.
- Gao C, Fu X, Chu Q, Li J, Shu G. Relationship between the ApoE gene polymorphism and type 2 diabetes mellitus complications. *Genet Test Mol Biomarkers.* 2021;25:111–5, <http://dx.doi.org/10.1089/gtmb.2020.0130>.
- Chen DW, Shi JK, Li Y, Yang Y, Ren SP. Association between ApoE polymorphism and type 2 diabetes: a meta-analysis of 59 studies. *Biomed Environ Sci.* 2019;32:823–38, <http://dx.doi.org/10.3967/bes2019.104>.
- Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. *BMC Med.* 2017;15:131, <http://dx.doi.org/10.1186/s12916-017-0901-x>.
- Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes – PMC. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002226/> [accessed 26.10.22].
- Stenvers DJ, Scheer FAJL, Schrauwen P, la Fleur SE, Kalsbeek A. Circadian clocks and insulin resistance. *Nat Rev Endocrinol.* 2019;15:75–89, <http://dx.doi.org/10.1038/s41574-018-0122-1>.
- Casasnovas JA, Alcaide V, Civeira F, Gualler E, Ibañez B, Borreguero JJ, et al. Aragon workers' health study – design and cohort description. *BMC Cardiovasc Disord.* 2012;12:45, <http://dx.doi.org/10.1186/1471-2261-12-45>.
- American Diabetes Association Professional Practice Committee 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. *Diabetes Care.* 2022;45 Suppl. 1:S17–38, <http://dx.doi.org/10.2337/dc22-S002>.
- Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. *Lancet.* 1995;346:120–1, [http://dx.doi.org/10.1016/s0140-6736\(95\)92143-5](http://dx.doi.org/10.1016/s0140-6736(95)92143-5).
- Mateo-Gallego R, Uzhova I, Moreno-Franco B, León-Latre M, Casasnovas JA, Laclaustra M, et al. Adherence to a Mediterranean diet is associated with the presence and extension of atherosclerotic plaques in middle-aged asymptomatic adults: the Aragon Workers' Health Study. *J Clin Lipidol.* 2017;11:1372–82, <http://dx.doi.org/10.1016/j.jacl.2017.08.007>, e4.
- Uzhova I, Mateo-Gallego R, Moreno-Franco B, Molina-Montes E, León-Latre M, Casasnovas JA, et al. The additive effect of adherence to multiple healthy lifestyles on subclinical atherosclerosis: Insights from the AWHs. *J Clin Lipidol.* 2018;12:615–25, <http://dx.doi.org/10.1016/j.jacl.2018.03.081>.
- de la Fuente-Arrillaga C, Ruiz ZV, Bes-Rastrollo M, Sampson L, Martínez-González MA. Reproducibility of an FFQ validated in Spain. *Public Health Nutr.* 2010;13:1364–72, <http://dx.doi.org/10.1017/S136898009993065>.

31. Lupiáñez-Barbero A, González Blanco C, de Leiva Hidalgo A. Tablas y bases de datos de composición de alimentos españolas: necesidad de un referente para los profesionales de la salud. *Endocrinol Diabetes Nutr.* 2018;65:361–73, <http://dx.doi.org/10.1016/j.endinu.2018.05.001>.
32. Baila-Rueda L, Pérez-Ruiz MR, Jarauta E, Tejedor MT, Mateo-Gallego R, Lamiquiz-Moneo I, et al. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes. *Atherosclerosis.* 2016;246:202–7, <http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.005>.
33. Team RC. R Foundation for Statistical Computing; Vienna, Austria: 2014. R: A language and environment for statistical computing. 2018:2013.
34. Anthopoulos PG, Hamodrakas SJ, Bagos PG. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. *Mol Genet Metab.* 2010;100:283–91, <http://dx.doi.org/10.1016/j.ymgme.2010.03.008>.
35. El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. *Cardiovasc Diabetol.* 2016;15:12, <http://dx.doi.org/10.1186/s12933-016-0329-1>.
36. Manodpitipong A, Saetung S, Nimitphong H, Siwasaranond N, Wongphan T, Sornsiriwong C, et al. Night-shift work is associated with poorer glycaemic control in patients with type 2 diabetes. *J Sleep Res.* 2017;26:764–72, <http://dx.doi.org/10.1111/jsr.12554>.
37. Bescos R, Boden MJ, Jackson ML, Trewin AJ, Marin EC, Levinger I, et al. Four days of simulated shift work reduces insulin sensitivity in humans. *Acta Physiol (Oxf).* 2018;223:e13039, <http://dx.doi.org/10.1111/apha.13039>.
38. Vetter C, Dashti HS, Lane JM, Anderson SG, Schernhammer ES, Rutter MK, et al. Night shift work, genetic risk, and type 2 diabetes in the UK biobank. *Diabetes Care.* 2018;41:762–9, <http://dx.doi.org/10.2337/dc17-1933>.
39. Reszka E, Wiecek E, Przybek M, Jabłońska E, Kałużny P, Bukowska-Damska A, et al. Circadian gene methylation in rotating-shift nurses: a cross-sectional study. *Chronobiol Int.* 2018;35:111–21, <http://dx.doi.org/10.1080/07420528.2017.1388252>.
40. Reszka E, Peplonska B, Wiecek E, Sobala W, Bukowska A, Gromadzinska J, et al. Rotating night shift work and polymorphism of genes important for the regulation of circadian rhythm. *Scand J Work Environ Health.* 2013;39:178–86, <http://dx.doi.org/10.5271/sjweh.3299>.
41. Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, et al. Glucose metabolism during rotational shift-work in healthcare workers. *Diabetologia.* 2017;60:1483–90, <http://dx.doi.org/10.1007/s00125-017-4317-0>.
42. Peñalvo JL, Mertens E, Muñoz-Cabrejas A, León-Latre M, Jarauta E, Laclaustra M, et al. Work shift, lifestyle factors, and subclinical atherosclerosis in Spanish male workers: a mediation analysis. *Nutrients.* 2021;13:1077, <http://dx.doi.org/10.3390/nu13041077>.
43. Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: a review. *Int J Health Sci (Qassim).* 2017;11:65–71.
44. Steyn NP, Mann J, Bennett PH, Temple N, Zimmet P, Tuomilehto J, et al. Diet, nutrition and the prevention of type 2 diabetes. *Public Health Nutr.* 2004;7:147–65, <http://dx.doi.org/10.1079/phn2003586>.
45. Hung T, Sievenpiper JL, Marchie A, Kendall CWC, Jenkins DJA. Fat versus carbohydrate in insulin resistance, obesity, diabetes and cardiovascular disease. *Curr Opin Clin Nutr Metab Care.* 2003;6:165–76, <http://dx.doi.org/10.1097/00075197-200303000-00005>.
46. Partearroyo T, Samaniego-Vaesken MdL, Ruiz E, Aranceta-Bartrina J, Gil Á, González-Gross M, et al. Current food consumption amongst the Spanish ANIBES study population. *Nutrients.* 2019;11:E2663, <http://dx.doi.org/10.3390/nu1112663>.
47. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. *Endocr Rev.* 2016;37:278–316, <http://dx.doi.org/10.1210/er.2015-1137>.